<DOC>
	<DOC>NCT02238080</DOC>
	<brief_summary>This observational, multi-center, open-label, prospective study will evaluate the relationship between serum interleukin-6 (IL-6) and C-reactive protein (CRP) levels and methoxy polyethylene glycol-epoetin beta dosage in participants with chronic kidney disease (CKD) on dialysis. Participants will be recruited who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy or will initiate therapy with methoxy polyethylene glycol-epoetin beta.</brief_summary>
	<brief_title>An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>CKD participants undergoing dialysis Participants initiating ESA treatment with methoxy polyethylene glycolepoetin beta or participants on stable methoxy polyethylene glycolepoetin beta maintenance therapy Adequate iron status defined as: serum ferritin above or equal to 100 micrograms per liter (mcg/L) or transferrin saturation above or equal to 20 percent (%) Conditions known to cause inadequate response to ESA treatment Anemia other than symptomatic anemia associated with CKD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>